Zimmer Biomet Holdings, Inc. $ZBH Shares Sold by Nixon Peabody Trust Co.

Nixon Peabody Trust Co. reduced its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 20.3% during the second quarter, HoldingsChannel reports. The firm owned 3,250 shares of the medical equipment provider’s stock after selling 830 shares during the quarter. Nixon Peabody Trust Co.’s holdings in Zimmer Biomet were worth $296,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Accent Capital Management LLC bought a new stake in shares of Zimmer Biomet in the first quarter worth $35,000. Cullen Frost Bankers Inc. increased its holdings in shares of Zimmer Biomet by 1,452.4% in the first quarter. Cullen Frost Bankers Inc. now owns 326 shares of the medical equipment provider’s stock valued at $37,000 after buying an additional 305 shares in the last quarter. Zions Bancorporation National Association UT acquired a new position in shares of Zimmer Biomet in the 1st quarter worth $48,000. Hilltop National Bank acquired a new stake in Zimmer Biomet during the 2nd quarter worth about $42,000. Finally, Brooklyn Investment Group lifted its position in shares of Zimmer Biomet by 45.9% in the 1st quarter. Brooklyn Investment Group now owns 461 shares of the medical equipment provider’s stock valued at $52,000 after acquiring an additional 145 shares in the last quarter. Institutional investors and hedge funds own 88.89% of the company’s stock.

Zimmer Biomet Stock Up 0.4%

ZBH opened at $90.36 on Friday. The business has a 50 day moving average of $98.88 and a 200-day moving average of $97.19. The stock has a market capitalization of $17.91 billion, a price-to-earnings ratio of 21.98, a P/E/G ratio of 2.29 and a beta of 0.67. The company has a current ratio of 1.87, a quick ratio of 0.96 and a debt-to-equity ratio of 0.54. Zimmer Biomet Holdings, Inc. has a 1-year low of $85.33 and a 1-year high of $114.72.

Zimmer Biomet (NYSE:ZBH) last released its earnings results on Wednesday, November 5th. The medical equipment provider reported $1.90 EPS for the quarter, beating the consensus estimate of $1.88 by $0.02. The firm had revenue of $2 billion during the quarter, compared to analysts’ expectations of $2.01 billion. Zimmer Biomet had a net margin of 10.51% and a return on equity of 12.76%. The business’s quarterly revenue was up 9.6% compared to the same quarter last year. During the same period in the prior year, the company earned $1.74 EPS. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. As a group, sell-side analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th were given a $0.24 dividend. The ex-dividend date was Tuesday, September 30th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.1%. Zimmer Biomet’s dividend payout ratio (DPR) is currently 23.76%.

Insider Buying and Selling at Zimmer Biomet

In other news, SVP Lori Winkler sold 1,500 shares of the business’s stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $104.15, for a total transaction of $156,225.00. Following the sale, the senior vice president directly owned 6,833 shares in the company, valued at approximately $711,656.95. The trade was a 18.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 0.70% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have commented on the company. Redburn Partners set a $130.00 price objective on Zimmer Biomet in a research report on Thursday, September 18th. Canaccord Genuity Group cut their target price on shares of Zimmer Biomet from $101.00 to $93.00 and set a “hold” rating for the company in a research report on Monday. Wall Street Zen raised shares of Zimmer Biomet from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. Rothschild Redb upgraded Zimmer Biomet to a “strong-buy” rating in a research note on Thursday, September 18th. Finally, Roth Capital reaffirmed a “buy” rating on shares of Zimmer Biomet in a research note on Thursday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, nine have given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, Zimmer Biomet currently has an average rating of “Hold” and a consensus price target of $109.00.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.